Progyny Q3 revenue up 2% to $286.6M, net income falls 34% to $10.4M; cuts FY2024 guidance

Progyny, Inc.

2024-Q3 EPS reported $0.46 revenue$868,790,000

Revenue $286.6M (+2% YoY); net income $10.4M ($0.11 diluted EPS) vs $15.9M ($0.16) in Q3 2023.
Adjusted EBITDA $46.5M (-7.1% YoY); margin 16.2% vs 17.8% a year ago.
Full-year 2024 revenue guidance lowered to $1.135-1.150B; adjusted EBITDA guidance $189-194M.
New sales season adds 80+ clients, 1.1M new covered lives; also selected by two health plans as preferred partner.
Q3 utilization rate lower than expected; members took longer to progress, consuming fewer treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.